Bioatla (BCAB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
31 Dec, 2025Executive summary
Special meeting adjourned to January 12, 2026, to allow more time for voting on the Reverse Stock Split Proposal.
Stockholders are requested to vote in advance, with voting closing on January 11, 2026.
Voting matters and shareholder proposals
Proposal to amend the Certificate of Incorporation to authorize a reverse stock split at a ratio between 1-for-5 and 1-for-20, at the board's discretion, any time before June 30, 2026.
Both ISS and Glass Lewis recommend supporting the Reverse Stock Split Proposal.
Board of directors and corporate governance
Board of directors will determine the final reverse split ratio within the approved range without further stockholder approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bioatla
- Stockholders to vote on a merger and share conversion at a reconvened meeting on March 23, 2026.BCAB
Proxy Filing2 Mar 2026 - Shareholders to vote on a 1-for-50 share consolidation to address Nasdaq listing compliance.BCAB
Proxy Filing11 Feb 2026 - Q2 2024 saw reduced net loss, clinical milestones, and cash runway through Q3 2025.BCAB
Q2 20242 Feb 2026 - Promising clinical data and pivotal trial plans drive optimism for CAB-based cancer therapies.BCAB
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - Vote on a 1-for-50 share consolidation merger to regain Nasdaq compliance and update governance.BCAB
Proxy Filing30 Jan 2026 - iNKT cell therapies show promise in cancer and ARDS, with pivotal trials and new programs underway.BCAB
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Up to $200M in securities offered, with $18.75M in equity deals to fund R&D and operations.BCAB
Registration Filing16 Jan 2026 - Stockholders will vote on a board-discretionary reverse stock split at the January 2026 meeting.BCAB
Proxy Filing15 Jan 2026 - Q3 2024 saw clinical progress, reduced losses, and a licensing deal extending cash runway to 2026.BCAB
Q3 202415 Jan 2026